A year ago, hoping to dispel the postpartum gloom that had gripped me
after I finished writing a book, I hiked into a forest near my home and
pitched a tent under some pine trees. I spent that day and evening
listening to the forest, scribbling in my journal, and thinking—all
while under the influence of a psychedelic drug. The next morning I
returned to my wife and children feeling better than I had in months.
What I did that day should not be illegal. Adults
seeking solace or insight ought to be allowed to consume psychedelics
such as LSD, psilocybin, and mescaline. U.S. laws now classify them as
Schedule 1 drugs, banned for all purposes because of their health risks.
But recent studies have shown that psychedelics—which more than 20
million Americans have ingested—can be harmless and even beneficial when
taken under appropriate circumstances.
Citing this research, some scholars and scientists are
proposing that the prohibitions against psychedelics—or entheogens, "God
engenderers," as believers in their spiritual benefits prefer to call
them—should be reconsidered. This legal issue has recently been brought
to a head by a religious sect in New Mexico that is suing the United
States for the right to drink a hallucinogenic tea called ayahuasca in
its ceremonies. A federal court is expected to rule on the potentially
momentous case any day now.
"There is no doubt that hallucinogens can be used
unwisely," says Charles Grob, a psychiatrist at the UCLA-Harbor Medical
Center, who testified in the ayahuasca case and is a leader of the
effort to rehabilitate the reputation of these substances. "But these
studies show that they can be used safely within certain parameters."
After LSD's astonishing effects were discovered by the
Swiss chemist Albert Hofmann 60 years ago, many psychiatrists considered
it and similar compounds potential treatments for psychological
ailments. That is why the psychiatrist Humphrey Osmond called the drugs
"psychedelic," from the Greek root for "mind-revealing." By the
mid-1960s, medical journals had published more than 1,000 papers
describing the treatment with psychedelics of some 40,000 patients
afflicted with disorders ranging from schizophrenia to alcoholism.
One remarkable study from this period, known as the
Good Friday experiment, probed the capacity of psilocybin (the active
ingredient of so-called magic mushrooms) to trigger spiritual
experiences. On Good Friday, 1962, the Harvard psychiatrist Walter
Pahnke dispensed psilocybin and placebos to a group of 30 divinity
students and professors assembled in a Boston church. A majority of
those who received psilocybin reported sensations of profound awe and
self-transcendence that had lasting positive effects.
By the early 1970s, the surging popularity of
psychedelics among the young—urged by Timothy Leary to "turn on, tune
in, and drop out"—had triggered a backlash. Psychedelics were outlawed,
and virtually all research on them was shut down amid rising concerns
about their adverse social and medical effects. In 1971, the Journal
of the American Medical Association warned that repeated
consumption of psychedelics would usually result in permanent
"personality deterioration."
Further research has shown these fears to be
exaggerated, says John Halpern, a psychiatrist at Harvard Medical
School. To be sure, psychedelics can cause acute and sometimes
persistent psychopathology, especially in those predisposed to mental
illness. But Halpern maintains that these compounds are usually harmless
when ingested by healthy individuals in appropriate settings.
As evidence, Halpern cites a five-year study he
recently completed with a Harvard colleague of members of the Native
American Church, who are permitted by U.S. law to consume the
mescaline-containing cactus peyote as a sacrament. Church members who
had taken peyote at least 100 times showed no adverse neurocognitive
effects compared to a control group.
Similar results have emerged from a study of ayahuasca
by UCLA psychiatrist Grob and other scientists, results that Grob
describes in the essay collection Hallucinogens. Ayahuasca, a
tea brewed from two Amazonian plants, contains the potent psychedelic
dimethyltryptamine, or DMT. Although the tea often triggers nausea and
diarrhea, Indian shamans have prized it for its visionary properties for
centuries, and since 1987 it has served as a legal sacrament for several
churches in Brazil. The largest is the Uniao Do Vegetal, or UDV, which
combines elements of Christianity with nature worship and claims 8,000
members.
Grob and his colleagues found
that UDV members were on average healthier physiologically and
psychologically than a control group. The UDV adherents also had
elevated receptors for the neurotransmitter serotonin, which has been
correlated with resistance to depression and other disorders. Many of
the UDV members told the scientists that ayahuasca had helped them
overcome alcoholism, drug addiction, and other self-destructive
behaviors.
These findings emboldened UDV adherents based in New
Mexico to sue the U.S. Justice Department for the right to drink their
sacrament. The case dates to 1999, when federal agents seized 30 gallons
of ayahuasca that the UDV group had imported from Brazil. Last August, a
federal judge in Albuquerque ruled in favor of the UDV worshippers. The
judge contended that the Justice Department had not shown that ayahuasca
poses enough of a health risk to warrant restricting the UDV members'
right to practice their religion. The Justice Department lawyers
appealed, and the case is now before the 10th Circuit Court
in Denver.
Of course, even advocates of entheogens admit that
they pose risks. Ayahuasca can cause cardiac irregularities and other
dangerous side effects, Grob notes, when combined with amphetamines,
antidepressants, cheese, red wine, and other common substances.
Ayahuasca drinkers generally fast before sessions to reduce the risks of
these side effects.
In the new book The Antipodes of the Mind,
an in-depth study of ayahuasca visions, the Israeli psychologist Benny
Shanon recalls that the tea transformed him from a "devout atheist" into
someone awestruck by the wonders of nature and of human consciousness.
But he warns that ayahuasca can also be "the worst of liars," leaving
some users gripped by belief in ghosts, telepathy, and other occult
phenomena. Similarly, in Cleansing the Doors of Perception, the
eminent religious scholar Huston Smith recalls that during the Good
Friday experiment, in which he participated, one subject became so
agitated that he had to be injected with Thorazine. Smith nonetheless
contends that entheogens can serve a spiritual purpose, if used with
reverence; after all, mind-altering substances have played an
inspirational role in many religions, including Hinduism and the
Eleusinian cult of ancient Greece.
I have firsthand experience of the double-edged nature
of entheogens, which I've taken sporadically since my late teens. There
have been moments of vertiginous anxiety; one particularly bad trip in
1981 left me with unsettling flashbacks for months. But overall the pros
have outweighed the cons. I usually end up feeling the way I did after
my LSD sojourn last summer: existentially refreshed, with a renewed
appreciation of ordinary existence.
Entheogens are far less addictive and toxic than
alcohol or tobacco. Why should we continue to be denied their benefits,
in religious or non-religious contexts? Risks could be minimized by
making these substances available only through licensed therapists, who
can screen clients for mental instability and advise them on how to make
their experiences as rewarding as possible. Some people might be
prescribed entheogens for a specific disorder, such as depression or
alcoholism. And just as drugs such as Prozac and Viagra are prescribed
not just to heal the ill but also to enhance the lives of the healthy,
so might entheogens.
This scenario may not be so far-fetched, given last
year's court decision favoring the UDV in New Mexico and other
developments. A sanctioned study of psilocybin's capacity for treating
obsessive-compulsive disorder is now under way at the University of
Arizona. And UCLA psychiatrist Grob recently received FDA approval to
investigate whether psilocybin can relieve anxiety in late-stage cancer
patients. Maybe those of us who enjoy an occasional psychedelic sojourn
will be able to do so without feeling like outlaws.
Wouldn't that be a trip?